These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2211702

  • 1. The selective inhibition of thrombin by peptides of boroarginine.
    Kettner C, Mersinger L, Knabb R.
    J Biol Chem; 1990 Oct 25; 265(30):18289-97. PubMed ID: 2211702
    [Abstract] [Full Text] [Related]

  • 2. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A, Mennecier P, Lila C, de Nanteuil G, Verbeuren TJ.
    Thromb Haemost; 1997 Oct 25; 78(4):1221-7. PubMed ID: 9364988
    [Abstract] [Full Text] [Related]

  • 3. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
    Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J.
    Thromb Res; 1994 May 01; 74(3):193-205. PubMed ID: 8042188
    [Abstract] [Full Text] [Related]

  • 4. The solution conformation of (D)Phe-Pro-containing peptides: implications on the activity of Ac-(D)Phe-Pro-boroArg-OH, a potent thrombin inhibitor.
    Lim MS, Johnston ER, Kettner CA.
    J Med Chem; 1993 Jun 25; 36(13):1831-8. PubMed ID: 8515421
    [Abstract] [Full Text] [Related]

  • 5. In vivo characterization of a new synthetic thrombin inhibitor.
    Knabb RM, Kettner CA, Timmermans PB, Reilly TM.
    Thromb Haemost; 1992 Jan 23; 67(1):56-9. PubMed ID: 1615483
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.
    Tapparelli C, Metternich R, Ehrhardt C, Zurini M, Claeson G, Scully MF, Stone SR.
    J Biol Chem; 1993 Mar 05; 268(7):4734-41. PubMed ID: 8444849
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ, Almond HR, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.
    J Med Chem; 2005 Mar 24; 48(6):1984-2008. PubMed ID: 15771442
    [Abstract] [Full Text] [Related]

  • 10. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats.
    Hussain MA, Knabb R, Aungst BJ, Kettner C.
    Peptides; 1991 Mar 24; 12(5):1153-4. PubMed ID: 1800952
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L.
    Thromb Haemost; 1994 Apr 24; 71(4):511-6. PubMed ID: 8052972
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of selective boron-containing thrombin inhibitors.
    Wienand A, Ehrhardt C, Metternich R, Tapparelli C.
    Bioorg Med Chem; 1999 Jul 24; 7(7):1295-307. PubMed ID: 10465405
    [Abstract] [Full Text] [Related]

  • 14. Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin.
    Reilly TM, Knabb RM, Hassell SM, Bozarth JM, Forsythe MS, Mayo MC, Racanelli AL, Mousa SA.
    Blood Coagul Fibrinolysis; 1992 Oct 24; 3(5):513-7. PubMed ID: 1450317
    [Abstract] [Full Text] [Related]

  • 15. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems.
    Kaiser B, Callas D, Hoppensteadt D, Mallinowska K, Fareed J.
    Thromb Res; 1994 Mar 01; 73(5):327-35. PubMed ID: 8016817
    [Abstract] [Full Text] [Related]

  • 16. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.
    Gaussem P, Dubar M, le Bonniec B, Richard-Lordereau I, Jochemsen R, Aiach M.
    Br J Clin Pharmacol; 2002 Feb 01; 53(2):147-54. PubMed ID: 11851638
    [Abstract] [Full Text] [Related]

  • 17. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.
    Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U.
    Am J Physiol; 1995 Mar 01; 268(3 Pt 2):H1352-7. PubMed ID: 7535008
    [Abstract] [Full Text] [Related]

  • 18. Highly selective tripeptide thrombin inhibitors.
    Shuman RT, Rothenberger RB, Campbell CS, Smith GF, Gifford-Moore DS, Gesellchen PD.
    J Med Chem; 1993 Feb 05; 36(3):314-9. PubMed ID: 8426361
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids.
    Kettner CA, Shenvi AB.
    J Biol Chem; 1984 Dec 25; 259(24):15106-14. PubMed ID: 6392293
    [Abstract] [Full Text] [Related]

  • 20. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.
    Yang XJ, Blajchman MA, Craven S, Smith LM, Anvari N, Ofosu FA.
    Biochem J; 1990 Dec 01; 272(2):399-406. PubMed ID: 2268268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.